Cybin to participate in psych symposium london 2023

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that amir inamdar, mbbs, dnb (psych), mfpm, cybin's chief medical officer, will be participating in the upcoming psych symposium 2023 taking place thursday, july 6, 2023 at the british museum in london, uk. dr. inamdar.
CYBN Ratings Summary
CYBN Quant Ranking